Search results for: Primary care

Letters to the Editor: In Memoriam

The Rheumatologist | January 1, 2010

One more prescribing rule [See “Rheuminations,” September 2009, p. 6], honored mainly in the breach, in our overspending climate: don’t prescribe an expensive brand when generics are as good or better, especially Nexium (which I have never prescribed) versus omeprazole, Lipitor versus simvastatin (which now costs the VA three cents a pill), and—for rheumatologists who are writing 80% Uloric—allopurinol except for the 10% who might need Uloric.

Is B a Key to Autoimmune Therapy?: B Cell–targeted Therapies in Autoimmune Disease

Jennifer Anolik, MD, PhD | January 1, 2010

A perspective on B cell–targeted therapies in autoimmune disease

Reading Rheum

Gail C. Davis, RN, EdD; Michael M. Ward, MD; | October 1, 2009

Handpicked Reviews of Contemporary Literature

I RheumPAC, Do You?

Jim Engelbrecht, MD | September 1, 2009

For many years, the ACR board of directors and Government Affairs Committee have done exemplary work in keeping members abreast of legislative regulatory issues that affect all aspects of rheumatology, including patient and physician/healthcare professional issues, education, and research. Through advocacy, the ACR advances rheumatology and fosters excellence in the care of people with, or at risk for, arthritis and rheumatic and musculoskeletal diseases. One might say that advocacy is a cornerstone of this organization.